A multicentre, prospective observation post-authorisation, open-label study of sublingual fentanyl tablets for relief of breakthrough pain in cancer patients and association with quality of life outcomes.

Trial Profile

A multicentre, prospective observation post-authorisation, open-label study of sublingual fentanyl tablets for relief of breakthrough pain in cancer patients and association with quality of life outcomes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Breast cancer; Cancer; Cancer pain; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Neuropathic pain; Prostate cancer; Visceral pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 New trial record
    • 25 Jul 2017 Results of subgroup (age more than or equal to 65 years and less than 65 years) analysis published in the Drugs in R and D
    • 01 Dec 2015 Primary end point (Short Form 12 (version 2) [SF-12v2] Physical Component Summary (PCS) score) has been met as per the results published in the Clinical Drug Investigation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top